Information Provided By:
Fly News Breaks for September 6, 2018
CPRX
Sep 6, 2018 | 16:10 EDT
Piper Jaffray analyst Joseph Catanzaro resumed coverage of Catalyst Pharmaceuticals with an Overweight rating and $5 price target. The analyst expects approval of lead product Firdapse before the end of 2018, allowing the company to access an orphan neuromuscular opportunity where there are no approved therapies. Before expiration of exclusivity in 2025, he believes Firdapse could achieve peak U.S. sales of $150M in this setting. Overall, Catanzaro thinks Firdapses could achieve U.S. sales of $300M-plus by 2025.
News For CPRX From the Last 2 Days
There are no results for your query CPRX
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.